Cochlear Limited is the global leader in implantable hearing solutions. Cochlear commenced operations in 1981 as part of the Nucleus group. In 1995, the company listed on the Australian Securities Exchange. Today, it is a global company with principal manufacturing facilities in Australia and Sweden, and additional manufacturing facilities in Belgium and the United States. Cochlear has its global headquarters on campus at Macquarie University in Sydney, Australia, with regional headquarters in Asia Pacific, Europe and the Americas. Cochlear has direct operations in 20 countries and 2,800 employees. Cochlear develops a range of products including cochlear implants, bone conduction implants and acoustic implants, which address different types of hearing loss. Whether these hearing solutions were implanted today or many years ago, Cochlear makes new technologies and innovations available to its recipients. The company invests more than AUS$100 million each year in research and development and currently participates in over 100 collaborative research programs worldwide. Over 450,000 people of all ages, across more than 100 countries, now hear because of Cochlear. And always’ – we aim to provide recipients with the best possible hearing and support for the rest of their lives. www.cochlear.com
